Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
ArQule Strikes Deal With Japan's Daiichi
by Lisa M. Jarvis
November 17, 2008
| A version of this story appeared in
Volume 86, Issue 46
ArQule has sealed two deals with Japanese drugmaker Daiichi Sankyo. In the first agreement, Daiichi will pay $60 million up front, as well as undisclosed milestone and royalty payments, for access to ArQule's ARQ 197, a small molecule that blocks Met, a protein implicated in some cancers. Separately, Daiichi will fork over $15 million plus research funding to use ArQule's kinase inhibitor discovery platform to find new anticancer drugs. The firms have launched a research collaboration that has already selected two kinase targets.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter